Generalised myasthenia gravis (gMG) in Pharmaceutical Benefits Scheme (PBS) 012-26020435

gMG is a rare autoimmune neuromuscular disorder that causes fluctuating muscle weakness due to impaired communication between nerves and muscles, typically affecting the eyes, face, limbs, swallowing and breathing.

Listing date: ravulizumab - 1 March 2026

See Written Authority Required Drugs for more details.

PBS-subsidised gMG treatment settings and time limits

• 3 months of acute treatment - 'acute severe gMG'
• 6 months of bridging therapy - 'bridging therapy for gMG'
• Continuous therapy - 'treatment refractory gMG'

A patient may transition forward from one phase to another where all criteria are met. This may include progressing from acute treatment to bridging therapy to continuous therapy, or directly from acute treatment to continuous therapy. However, a patient cannot return to an earlier treatment setting once they have progressed to a later one.

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.